So far, minimal residual disease (MRD) has not been used much outside of clinical trials, but researchers are testing how it might be used to guide decisions in clinical practice, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
So far, minimal residual disease (MRD) has not been used much outside of clinical trials, but researchers are testing how it might be used to guide decisions in clinical practice, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
Transcript
How can MRD being used to tailor therapy for patients with CLL? And is this being used in the real-world or most in clinical trials?
MRD, really at this point, has been a tool used for decision making in the context of clinical trials. More challenging in clinical practice, just given availability of testing and all of these things. So, right now I think the major use is in clinical trials, but I think as we know more about how MRD should inform our decision making it will become more a piece of clinical practice.
You were part of a team of authors on an abstract proposing a trial to assess MRD for the purpose of guiding clinical decision making. What was involved in that trial design and how would it help guide future decisions?
So, this is a really exciting study. We’re looking at patients who’ve [received a] commercial supply of venetoclax, either alone or in combination with a CD20 antibody, and 4 patients who have received this therapy will be testing MRD. And if patients have really achieved a deep level of response, they’ll be able to come off drug, and we’ll monitor MRD serially. We’re going to wait until patients really progress to re-treat the with venetoclax, but we will be seeing what the kinetics of that MRD is after stopping venetoclax.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More